Ushering in what Biogen Inc. CEO and chairman James Mullen called "an exciting time for us and hopefully an exciting time for our investors," the FDA approved Biogen's Amevive for psoriasis, giving Biogen the first biologic treatment for that indication. (BioWorld Today)

Ushering in what Biogen Inc. CEO and chairman James Mullen called "an exciting time for us and hopefully an exciting time for our investors," the FDA approved Biogen's Amevive for psoriasis, giving Biogen the first biologic treatment for that indication. (BioWorld Today)